5 Penny stocks worth noting from Monday’s trading session

Jeff Broth

Penny stock traders had plenty of stocks to follow on Monday, some of which offered daily returns that far exceed the yearly return of a major index

By Jeff Broth.

Jeff Broth is a business writer, mentor, and financial advisor. He has been consulting for SMBs and entrepreneurs for the past seven years.

U.S. equity markets are on track to end 2020 on a high note as the bull rebound off March’s lows appears to still have legs. While long term-investors are banking on another year of stable 6% to 10% annual returns, some of the top penny stocks rewarded investors with much larger returns in a fraction of the time.

Here is a summary of some of the more notable penny stocks that attracted the attention of traders on Monday and offered the potential for far superior returns.

BioCardia Doubles After Heart Failure Trial Results

BioCardia, Inc. (NASDAQ: BCDA) is a developer of therapies to treat cardiovascular and respiratory diseases. On Monday, the company said it expects to receive feedback from the data safety monitoring board (DSMB) by the end of Tuesday regarding interim data from its Phase 3 pivotal trial.

The company is currently examining the safety and efficacy of its CardiAMP cell therapy for the treatment of patients with ischemic heart failure. Investors and traders were optimistic that forthcoming data from the study could lead the FDA to approve its therapy to treat the large and unmet clinical need.

Shares of BioCardia opened Monday at $3.11 and rose to a new 52-week high of $6.95 before losing a lot of momentum. But the stock closed Monday at $4.48, good for a daily gain just shy of 60%.

Source: Google Finance

Synlogic Advances Clinical Stage Trial

Synlogic, Inc. (NASDAQ: SYBX) designs medicines that target validated underlying biology to treat diseases. The company’s main product line is Synthetic Biotic that is used for the treatment of metabolic disorders.

On Monday, traders bought Synlogic’s stock after the company said its investigational drug called SYNB1891 for the treatment of solid tumors and lymphoma advanced into a combination therapy stage of its ongoing Phase 1 trial.

Ongoing and interim results show so far that SYNB1891 is safe and well-tolerated and full Phase 1 results will be presented at a future medical meeting.

Shares of Synlogic opened for trading Monday morning at $3.03 and drifted lower throughout the trading session. The stock closed at $2.54, good for a 14% daily gain.

Source: Google Finance

Amarin Announces Scientific Findings, Analyst Sees 380% Upside Potential

Amarin Corporation (NASDAQ: AMRN) is a pharmaceutical company dedicated to improving cardiovascular health. Its lead product is called VASCEPA and is available by prescription in several countries, including the U.S. and Canada.

On Monday, the company detailed scientific findings it presented during a virtual scientific presentation. What may have attracted traders’ attention is the company’s exposure as a COVID-19 play.

Amarin detailed how an ongoing trial of COVID-19 positive patients showed those who received VASCEPA saw a 52% reduction in symptoms versus just a 24% reduction observed in people who received standard usual care.

While Amarin’s stock barely ended higher on Monday, analysts at research firm Piper Sandler highlighted in a note their expectations for “tremendous upside” to $19 per share, or roughly 380% upside.

Source: Google Finance

AnPac Bio-Medical Science Co Progresses In Cancer Treatment

AnPac Bio-Medical ScienceCo (NASDAQ: ANPC) is a biotechnology that focuses on early cancer screening and detection. The company’s CDA (Cancer Differentiation Analysis) platform has been shown to detect the risk of more than 20 different types of cancer with high sensitivity and specificity.

On Monday, the company said in a business update its technology and processes made significant progress in detecting pre-cancer diseases.

The announcement follows the completion of a prospective large population screening consisting of 110,000 individuals and more than 150,000 samples using its CDA technology and a follow-up study of 13,000. Initial results showed its platform was able to screen out and confirm pre-cancer cases at roughly 4.5 times that of cancer cases.

“From a commercialization perspective, this breakthrough has significant ramifications for market and customer needs, and revenue generation potential,” AnPac Bio Chairman and CEO Dr. Chris Yu said in the press release.

Shares of AnPac opened for trading Monday at $8.45 and quickly hit a daily high of $8.65 before losing momentum and ending the day at $5.70, good for a 35% daily return.

Source: Google Finance

Aerpio Pharmaceuticals Plunges After Mixed Phase 2 Results

Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) is a biopharmaceutical company focused on treating ocular diseases and diabetic complications along with other indications. The company’s lead compound is called razuprotafib and is being developed as a potential treatment for open angle glaucoma.

On Monday, the company released mixed results from a Phase 2 study of its razuprotafib. On the positive side, razuprotafib along with a combination of latanoprost demonstrated a statistically significant improvement after 28 compared to those treated with just a latanoprost monotherapy.

However, what seems to have attracted the attention of bears and penny stock short sellers was the company’s acknowledgment that the razuprotafib once-daily dose group did not show a statistically significant improvement over the same 28-day period.

Shares of Arepa opened Monday at $1.22 which marks a notable decline from Friday’s close of $2.25. The stock ended the day near where it started at $1.20 which implies a decline of more than 45%.

Source: Google Finance

The subject matter and the content of this article are solely the views of the author. FinanceFeeds does not bear any legal responsibility for the content of this article and they do not reflect the viewpoint of FinanceFeeds or its editorial staff.

Read this next

Retail FX

Banxso announces 8.7% interest rate on deposits in South Africa

“With Banxso, they can enjoy the benefits of both worlds – earning competitive interest and having the freedom to trade, all within the same platform.”

Industry News

FINRA to publish transaction details in U.S. Treasury securities

“Consistent with our longstanding practice, FINRA is introducing greater transparency in a calibrated and careful manner, benefiting liquidity and resilience in this critical market while also mitigating potential information leakage concerns.”

Institutional FX

OpenYield launches “cheap and easy” fixed income trading for brokers

“We’re on a mission to make bonds cheap and easy to trade, and are excited about the opportunity to build generational capital markets infrastructure.”

Digital Assets

Sumsub and Mercuryo publish a guide for VASPs: “Mastering Travel Rule Compliance”

“At Sumsub, we’ve concentrated our efforts on filling the gap in understanding the complexity of Travel Rule regulation and helping organizations find the best solution to stay safe and compliant while minimizing costs and avoiding potential risks of non-compliance. This guide we created with Mercuryo, our trusted partner, is the ultimate navigation tool all VASPs can consult.”

Digital Assets

Bitget Wallet Leads with Record Swap Volume & New Crypto Innovations

This week, Bitget Wallet achieved a milestone by surpassing Metamask with a record 388,757 Swap order transactions, securing the global lead. The significant 7-day trading volume, almost 68,000 more than its rival, underscores its liquidity and user trust. This robust activity signals Bitget Wallet’s prominent role and reliability in the dynamic crypto market.

Digital Assets

Embarking on a Digital Currency Journey

Imagine you’ve stumbled upon a treasure map, leading you to untold riches hidden in the vastness of the internet. Instead of gold coins and jewel-encrusted goblets, this treasure comes in the form of digital currencies, the modern-day loot coveted by many.

Reviews

Traders Union Experts Share The Trading Analyst Review For 2024

Navigating options trading in rapidly shifting markets poses a considerable challenge. This is where options trading alert services become invaluable. They aid traders in keeping abreast of evolving opportunities and market trends. In this assessment, Traders Union experts scrutinize The Trading Analyst alert service to ascertain its efficacy. 

Digital Assets

BlockDAG’s Presale Achieves $9.9M: Aiming For A 5000-Fold ROI As Cardano’s Price Rises And Fantom Launches Sonic

Explore Cardano’s surge, Sonic’s efficiency, and why BlockDAG’s growth makes it the top crypto choice. A deep dive into the future of blockchain investments.

Digital Assets

US, UK probe $20 billion Tether transfers tied to Russian exchange.

U.S. and UK authorities are investigating the movement of $20 billion in the USD-pegged stablecoin tether (USDT) through Moscow-based exchange Garantex.

<